Oncology research company Charm Therapeutics has signed for B900 at the Babraham Research Campus in Cambridge.
The 13,569 sq ft facility will be used as a new research and development site to support the company’s growth plans.
The move follows
Thank you for reading EG
Want to read more? Enjoy a story a day for FREE for one month.
